Zymeworks Inc.ZYMEEarnings & Financial Report
Zymeworks Inc. is a publicly held biotechnology company based in Vancouver, British Columbia, that develops protein therapeutics for the treatment of cancer as well as for autoimmune and inflammatory diseases. The products are based upon the company's molecular modeling software for optimizing protein structure. In 2014, Zymeworks raised $44 million across various funding rounds according to PitchBook, placing it among the top 10 HealthTech businesses in the world to raise the most capital th...
ZYME Q3 FY2025 Key Financial Metrics
Revenue
$27.6M
Gross Profit
N/A
Operating Profit
$-22.1M
Net Profit
$-19.6M
Gross Margin
N/A
Operating Margin
-80.1%
Net Margin
-71.0%
YoY Growth
72.6%
EPS
$-0.26
Zymeworks Inc. Q3 FY2025 Financial Summary
Zymeworks Inc. reported revenue of $27.6M (up 72.6% YoY) for Q3 FY2025, with a net profit of $-19.6M (up 34.3% YoY) (-71.0% margin).
Key Financial Metrics
| Total Revenue | $27.6M |
|---|---|
| Net Profit | $-19.6M |
| Gross Margin | N/A |
| Operating Margin | -80.1% |
| Report Period | Q3 FY2025 |
Zymeworks Inc. Annual Revenue by Year
Zymeworks Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $76.3M).
Zymeworks Inc. Quarterly Revenue & Net Profit History
Zymeworks Inc. results over the last 7 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $27.6M | +72.6% | $-19.6M | -71.0% |
| Q2 FY2025 | $48.7M | +153.2% | $2.3M | 4.8% |
| Q1 FY2025 | $27.1M | +170.3% | $-22.6M | -83.5% |
| Q4 FY2024 | $31.0M | +83.3% | $-23.5M | -75.8% |
| Q3 FY2024 | $16.0M | -3.1% | $-29.9M | -186.6% |
| Q2 FY2024 | $19.2M | +174.8% | $-37.7M | -195.8% |
| Q1 FY2024 | $10.0M | -71.8% | $-31.7M | -315.6% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $10.0M | $19.2M | $16.0M | $31.0M | $27.1M | $48.7M | $27.6M |
| YoY Growth | -71.8% | 174.8% | -3.1% | 83.3% | 170.3% | 153.2% | 72.6% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Assets | $553.8M | $515.6M | $487.2M | $463.1M | $425.5M | $408.4M | $397.3M |
| Liabilities | $115.8M | $109.5M | $120.2M | $124.3M | $100.6M | $73.9M | $77.2M |
| Equity | $438.0M | $406.2M | $367.0M | $338.8M | $325.0M | $334.5M | $320.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|
| Operating CF | $-37.7M | $-25.0M | $-5.9M | $-41.5M | $-3.4M | $12.1M | $-31.4M |